​

Adaptimmune Therapeutics (ADAP) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Adaptimmune Therapeutics Revenue Highlights

Latest Revenue (Y)

$178.03M

Latest Revenue (Q)

$7.29M

Main Segment (Y)

Development revenue

Adaptimmune Therapeutics Revenue by Period

Adaptimmune Therapeutics Revenue by Year

DateRevenueChange
2024-12-31$178.03M195.34%
2023-12-31$60.28M122.05%
2022-12-31$27.15M341.50%
2021-12-31$6.15M55.36%
2020-12-31$3.96M252.76%
2019-12-31$1.12M-98.11%
2018-12-31$59.51M57.28%
2017-12-31$37.83M166.47%
2016-12-31$14.20M32.43%
2015-06-30$10.72M1673.22%
2014-06-30$604.63K100.00%
2013-06-30--

Adaptimmune Therapeutics generated $178.03M in revenue during NA 2024, up 195.34% compared to the previous quarter, and up 15867.38% compared to the same period a year ago.

Adaptimmune Therapeutics Revenue by Quarter

DateRevenueChange
2025-03-31$7.29M126.10%
2024-12-31$3.22M-92.12%
2024-09-30$40.90M-68.10%
2024-06-30$128.23M2158.38%
2024-03-31$5.68M2336.82%
2023-12-31$233.01K-96.82%
2023-09-30$7.32M42.67%
2023-06-30$5.13M-89.22%
2023-03-31$47.60M331.64%
2022-12-31$11.03M57.39%
2022-09-30$7.01M26.53%
2022-06-30$5.54M54.91%
2022-03-31$3.58M152.29%
2021-12-31$1.42M17.79%
2021-09-30$1.20M-61.13%
2021-06-30$3.10M613.13%
2021-03-31$434.00K-71.11%
2020-12-31$1.50M25.90%
2020-09-30$1.19M137.65%
2020-06-30$502.00K-34.03%
2020-03-31$761.00K4.53%
2019-12-31$728.00K207.17%
2019-09-30$237.00K50.96%
2019-06-30$157.00K100.00%
2019-03-31--100.00%
2018-12-31$1.48M-96.37%
2018-09-30$40.79M351.34%
2018-06-30$9.04M10.27%
2018-03-31$8.20M91.94%
2017-12-31$4.27M-84.29%
2017-09-30$27.18M672.08%
2017-06-30$3.52M23.24%
2017-03-31$2.86M-66.53%
2016-12-31$8.54M253.31%
2016-09-30$2.42M636.59%
2016-06-30$328.00K-88.76%
2016-03-31$2.92M-25.94%
2015-09-30$3.94M100.00%
2015-03-31--100.00%
2014-12-31$2.27M47.92%
2014-09-30$1.53M-

Adaptimmune Therapeutics generated $7.29M in revenue during Q1 2025, up 126.10% compared to the previous quarter, and up 3126.49% compared to the same period a year ago.

Adaptimmune Therapeutics Revenue Breakdown

Adaptimmune Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 23Dec 22Dec 21Dec 20
Product revenue, net$1.24M----
Development revenue$176.80M$60.28M$27.15M$6.15M-
Development And Service----$3.96M

Adaptimmune Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Development revenue (99.31%), and Product revenue, net (0.69%).

Quarterly Revenue by Product

Product/ServiceJun 25Mar 25Dec 24Sep 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Product revenue, net$11.08M$4.05M------------------
Development revenue$2.60M$3.24M$135.90M$40.90M$7.55M$5.13M$47.60M$11.03M$7.01M$5.54M$3.58M$1.20M--------
Development And Service------------$3.10M$434.00K$1.50M$1.19M$502.00K$761.00K$728.00K$237.00K

Adaptimmune Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Product revenue, net (81.00%), and Development revenue (19.00%).

Adaptimmune Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
ADAPAdaptimmune Therapeutics$178.03M$7.29M
LPCNLipocine$11.20M$114.57K
ANLAdlai Nortye$5.00M$2.50M
BLRXBioLineRx$4.80M$6.86M
ERNAErnexa Therapeutics$582.00K-
GOVXGeoVax Labs-$852.28K
APLMApollomics--
OSRHOSR-$1.14M
MBRXMoleculin Biotech--
THARTharimmune--
LNAILunai Bioworks--

ADAP Revenue FAQ

What is Adaptimmune Therapeutics’s yearly revenue?

Adaptimmune Therapeutics's yearly revenue for 2024 was $178.03M, representing an increase of 195.34% compared to 2023. The company's yearly revenue for 2023 was $60.28M, representing an increase of 122.05% compared to 2022. ADAP's yearly revenue for 2022 was $27.15M, representing an increase of 341.50% compared to 2021.

What is Adaptimmune Therapeutics’s quarterly revenue?

Adaptimmune Therapeutics's quarterly revenue for Q1 2025 was $7.28M, a 126.10% increase from the previous quarter (Q4 2024), and a 28.30% increase year-over-year (Q1 2024). The company's quarterly revenue for Q4 2024 was $3.22M, a -92.12% decrease from the previous quarter (Q3 2024), and a 1282.78% increase year-over-year (Q4 2023). ADAP's quarterly revenue for Q3 2024 was $40.9M, a -68.10% decrease from the previous quarter (Q2 2024), and a 458.83% increase year-over-year (Q3 2023).

What is Adaptimmune Therapeutics’s revenue growth rate?

Adaptimmune Therapeutics's revenue growth rate for the last 3 years (2022-2024) was 555.78%, and for the last 5 years (2020-2024) was 4398.03%.

What are Adaptimmune Therapeutics’s revenue streams?

Adaptimmune Therapeutics's revenue streams in c 24 are Product revenue, net, and Development revenue. Product revenue, net generated $1.24M in revenue, accounting 0.69% of the company's total revenue Development revenue generated $176.8M in revenue, accounting 99.31% of the company's total revenue, up 193.29% year-over-year.

What is Adaptimmune Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Adaptimmune Therapeutics was Development revenue. This segment made a revenue of $176.8M, representing 99.31% of the company's total revenue.